Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human Phase 1 clinical trial of its personalized immunotherapy platform, Membrex™, in combination with an immune checkpoint inhibitor for the treatment of early stage and metastatic triple negative breast cancer

Next Previous
X
Search
Trial Profile

A first-in-human Phase 1 clinical trial of its personalized immunotherapy platform, Membrex™, in combination with an immune checkpoint inhibitor for the treatment of early stage and metastatic triple negative breast cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous immunotherapy Metaclipse Therapeutics (Primary)
  • Indications Early breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 23 Oct 2024 New trial record
    • 21 Oct 2024 According to Metaclipse Therapeutics media release, awarded $2 million by the National Cancer Institute (NCI) to support this phase 1 clinical trial to evaluate its personalized immunotherapy platform, Membrex™ in combination with immune checkpoint inhibition in early stage and metastatic triple negative breast cancer (TNBC), in partnership with Winship Cancer Institute and Emory University.
    • 21 Oct 2024 According to Metaclipse Therapeutics media release, company obtained clearance of its investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top